Search

Adam Sampson-Johannes Phones & Addresses

  • 3434 Grasswood Dr, El Sobrante, CA 94803 (510) 223-6267

Publications

Us Patents

Selective Killing And Diagnosis Of P53+ Neoplastic Cells

View page
US Patent:
62968459, Oct 2, 2001
Filed:
Nov 12, 1998
Appl. No.:
9/190930
Inventors:
Adam Sampson-Johannes - Berkeley CA
David Kirn - Mill Valley CA
Assignee:
Onyx Pharmaceuticals Inc. - Richmond CA
International Classification:
A61K 4800
C12N 15861
C12N 1563
C12Q 170
US Classification:
424 932
Abstract:
Methods and compositions for treating and diagnosing neoplastic disease using viruses are provided. Preferably, mutant adenovirus lacking viral proteins which bind and/or inactivate p53 are administered to a patient having a neoplasm which comprises cells exhibiting p53 and lacking, or substantially devoid of mismatch repair activity. The mutant virus is able to substantially produce a replication phenotype in such neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 function. The preferential generation of a replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.
Adam Sampson-Johannes from El Sobrante, CA Get Report